Rana R. McKay
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (73)
Sensitivity analysis: non-MSI-H comparison. (A) Standardized mean difference is shown for features pre- and post- adjustment for the TMB10+ cohort. Propensity-adjusted comparison of ICI (tTMB≥10) vs. taxanes (any tTMB level) is shown for (B) TTNT and (C) OS among the cohort excluding MSI-H.
Year:
2026
Purpose: Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC. Experimental Design: This study used the United States–based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with single-agent ICI or taxane. Results: Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%). In 84 ICI-treated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0.18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0.18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB Conclusions: These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable.
Year:
2026
Introduction We evaluated the incidence of anxiety, depression, and suicidality amongst TC survivors and the impact of chemotherapy on these outcomes. Methods We conducted a retrospective cohort study of men diagnosed with TC in the United States Veterans Affairs Health System from 1990 to 2016. De novo anxiety or depression was a composite endpoint comprised of diagnosis codes for anxiety, depression, or medications used to treat these diagnoses. Incident suicidality was defined as a diagnosis code for suicidal ideation. 2022 TC patients were compared in a 1:3 ratio to 6375 controls. Cox proportional hazards models were employed for statistical analysis. Results Mean age at diagnosis was 42.6 years. 5‐year cumulative incidence of anxiety or depression was 53.4% in TC patients and 35% for controls ( p < 0.001). TC patients were more likely to develop anxiety or depression (HR 1.66, 95% CI 1.56–1.78, p < 0.001) and suicidality (HR 22.99, 95% CI 17.52–30.17, p < 0.001). In the TC cohort, factors associated with a higher risk of anxiety or depression were divorce (HR 1.15, 95% CI 1.00–1.32, p = 0.044), unemployment (HR 1.68, 95% CI 1.47–1.9, p < 0.001), and receipt of chemotherapy (HR 1.20, 95% CI 1.06–1.35, p < 0.001). Conclusions Psychological morbidity due to depression, anxiety, and suicidality is high among TC survivors. In our analysis chemotherapy increases the rates of psychosocial morbidity. Clinicians should be proactive in screening and intervening for these diagnoses in TC survivors to provide early intervention and improve health comes.
Year:
2026
Background The expansion of treatment options for prostate cancer (PC) has improved disease‐specific and overall survival outcomes but has also raised questions about the optimal level of treatment needed for patients based on their individual prognosis and accounting for potential toxicity, incorporating quality of life considerations. Methods A panel of experts met to discuss current controversies in the care of patients with PC across the disease continuum. Multidisciplinary experts review advances and persistent uncertainties in biomarker‐guided assessment, imaging, and systemic therapy for prostate cancer. The discussion outlines priority gaps in evidence that must be addressed to optimize individualized patient care. Results Workshop topics included use of genomic biomarkers and artificial intelligence‐guided tools to identify and manage high‐risk and very‐high risk localized disease, management of biochemical recurrence, identification of patients with metastatic hormone‐sensitive PC who warrant treatment escalation, radiopharmaceutical therapy for metastatic castration‐resistant PC including optimal sequencing of approved therapies, role of imaging in identification and management of extraprostatic disease, and lifestyle interventions to optimize survivorship. Conclusions Many questions remain about management of PC related to biomarker‐based risk stratification to guide treatment selection, use of prostate‐specific membrane antigen‐positron emission tomography, and balancing the risk for PC‐related death with risks for treatment‐related toxicity. Ongoing research efforts are needed to optimize risk‐based treatment, sequence of therapies throughout the disease continuum, and survivorship care.
Year:
2026
PURPOSE Increased heterogeneity in outcomes has been observed postnephrectomy in patients with renal cell carcinoma (RCC), with standard clinical parameters being primarily used for risk assessment. Currently, no blood-based biomarkers are available for molecular residual disease (MRD) detection in RCC. Herein, we performed a multicenter, real-world evaluation of the prognostic value of circulating tumor DNA (ctDNA) in resected RCC. METHODS This real-world evidence-based multi-institutional study included a cohort of 77 patients with stage I-IV RCC. Longitudinal ctDNA testing was performed on plasma samples (n = 295) using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc, Austin, TX). ctDNA results were analyzed, and association with recurrence-free survival was assessed. RESULTS The patient cohort included 77 patients with stage I-IV RCC (clear cell: 64, non–clear cell: 13). Patients who tested ctDNA-positive during the MRD window experienced worse prognosis and a higher likelihood of recurrence (hazard ratios, 18; P < .0001) compared with their ctDNA-negative counterparts. CONCLUSION Overall, we demonstrate the utility of ctDNA testing for MRD detection. Future prospective studies in RCC would be needed to validate the utility of ctDNA in informing clinical decision making.
Year:
2026
Introduction The 12th Annual 2025 Coffey—Holden Prostate Cancer Academy (CHPCA) Meeting, “Deciphering Resistance: Beyond the Androgen Paradigm,” was held at the University of California, Los Angeles (UCLA), Luskin Conference Center, in Los Angeles, CA, from June 19 to 22, 2025. Methods The CHPCA Meeting is a discussion‐focused conference held annually by the Prostate Cancer Foundation (PCF), for in‐depth academic analysis of emerging research with the greatest potential to drive new understandings and treatments for prostate cancer. The 2025 CHPCA Meeting included attendance by 79 academic investigators and 39 talks over 8 sessions. Results The session topics included: drug discovery in academia, non‐apoptotic cell death mechanisms, understanding and overcoming treatment resistance, chromosomal instability (CIN) as a driver of metastasis and treatment resistance, targeting metastatic sites, immunotherapy sensitizers, and optimizing therapy delivery and biomedical engineering. Discussion This meeting report summarizes the presentations from the 2025 CHPCA Meeting. We hope that disseminating this information will directly contribute to novel research efforts and improved treatment strategies for patients with prostate cancer.
Year:
2025
Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).
Year:
2025
Purpose: Homologous recombination/DNA damage repair (HRR) alterations (HRRalt) are found in around 30% of patients with advanced prostate cancer and have been associated with worse prognosis in the metastatic castrate-resistant setting. However, there are limited data with regard to their association with outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Experimental Design: This study used a de-identified nationwide (U.S.-based) prostate cancer clinico-genomic database. Patients with de novo mHSPC treated with androgen deprivation therapy intensification with either an androgen receptor pathway inhibitor (ARPI) or a taxane who underwent tissue biopsy within 90 days of mHSPC diagnosis were included. Time to castrate resistance (TTCR) and overall survival (OS) were compared between patients with non-altered HRR and those with HRRalt in any of 14 prespecified genes per the olaparib monotherapy FDA label. TTCR and OS indexed from mHSPC diagnosis were evaluated with Cox proportional hazard models adjusted for baseline prognostic factors. Results: Of 637 eligible patients included in our analysis, 181 harbored HRRalt (28.4%). Compared with patients with non-altered HRR, those with HRRalt had less favorable TTCR when treated with an ARPI [adjusted HR (aHR) = 1.58; 95% confidence interval (CI), 1.17–2.14] or a taxane (aHR = 1.77; 95% CI, 1.3–2.4). Additionally, OS was directionally less favorable in patients with HRRalt (ARPI: aHR = 1.12; 95% CI, 0.80–1.57 and taxane: aHR = 1.23; 95% CI, 0.88–1.72). Conclusions: To date, this is the largest real-world natural history study evaluating the association of HRRalt with outcomes in the mHSPC setting. These data may inform future clinical trial design and counseling of these patients. See related commentary by Graham and Yu, p. 4001
Year:
2025
Outcomes on ARPI or taxane by CDK12alt status. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + ARPI for (A) TTCRPC and (C) OS. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.
Year:
2025
Outcomes on ARPI or taxane by ATMalt status. Outcomes for ATMalt vs. no ATMalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for ATMalt vs. no ATMalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (81)
Aditya Bagrodia
University of Texas Southwestern
Andrew Armstrong
Professor
Duke Cancer Institute
William Huang
Professor (Clinical)
New York University Grossman School of Medicine
Ulka Vaishampayan
Professor
University of Michigan
David Braun
Assistant Professor, Principal Investigator
Yale University Yale Cancer Center
Oliver Sartor
Tulane University School of Medicine
Pedro Barata
Associate Professor of Medicine
University Hospitals Seidman Cancer Center
John Lozada
University of Rochester Medical Center
Benedito A. Carneiro
-
George Sledge
-
Grace Blitzer
University of Wisconsin-Madison
Bose Kochupurakkal
Senior Scientist
Dana-Farber Cancer Institute
Phillip Palmbos
Assistant Professor
University of Michigan Hospital
Tian Zhang
University of Texas Southwestern
Amirali Salmasi
Associate Professor
UC San Diego Health System
Joshua Lang
Professor
University of Wisconsin-Madison
Natalie Reizine
Assistant Professor
University of Chicago
Arul M Chinnaiyan
University of Michigan
Eliezer Van Allen
Professor
Harvard University
Scott Tagawa
Weill Cornell Medicine
Emil Lou
University of Minnesota
Biren Saraiya
Assistant Professor of Medicine
Rutgers Cancer Institute of New Jersey
Ari VanderWalde
Global Head of Clinical Trials
-
Young Whang
University of North Carolina at Chapel Hill School of Medicine
Rahul Parikh
Associate Professor of Medicine
University of Kansas Medical Center
Eugene Shenderov
Associate Professor
Johns Hopkins University School of Medicine
Kent Mouw
Assistant Professor
Dana-Farber Cancer Institute
HAMID EMAMEKHOO
University of Wisconsin-Madison
Justin E. Wilson
Associate Professor
-
Alicia Morgans
Dana-Farber Cancer Institute
Justin Hwang
Associate Professor
University of Minnesota
Shuang G. Zhao
University of Wisconsin-Madison
Chadi Hage Chehade
Huntsman Cancer Institute
Toni Choueiri
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Wenxin Xu
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Jinhua Wang
professor
University of Minnesota System
Umang Swami
University of Utah
Rohan Garje
Clinical Associate professor
Iowa State University
Daniel J. George
Professor
Duke University
Elisabeth I. Heath
Wayne State University School of Medicine
Stacy Loeb
Professor
NYU School of Medicine
Azhar Khandekar
National Cancer Institute
Zeynep Irem Ozay
University of Utah Health Huntsman Cancer Institute
Alan Haruo Bryce
Chief Clinical Officer
City of Hope
David Kosoff
University of Wisconsin-Madison
Noel Warfel
Associate Professor
Medical University of South Carolina
Josep Domingo-Domenech
Professor
Mayo Clinic
Heather H. Cheng
Professor
University of Washington
Menggang Yu
Professor
University of Michigan
Jacob Orme
Assistant Professor
Mayo Clinic
Ludmil Alexandrov
Professor
University of California, San Diego
Scott M Dehm
Faculty, Professor
University of Minnesota
Marina N Sharifi
Assistant Professor
University of Wisconsin-Madison
Neal Lindeman
Vice Chair, Molecular Pathology and Laboratory Medicine
Weill Cornell Medicine
Anne Cress
Professor
University of Arizona
Nischalan Pillay
Professor
University College London
Emmanuel S. Antonarakis
-
Carly Miller
University of Minnesota
Jonathan Chou
Assistant Professor
University of California, San Francisco
Jeffrey S Miller
University of Minnesota System
Felix Y. Feng
University of California
Atish Choudhury
Dana-Farber Cancer Institute
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Shailender Singh Chauhan
Staff Scientist II
Medical University of South Carolina
Charles Nguyen
Assistant Clinical Professor
City Of Hope National Medical Center
Megan E.V. Caram
University of Michigan
Peter S. Nelson
Fred Hutchinson Cancer Research Center
Adam Olson
Assistant Professor
UPMC Hillman Cancer Center
Brent Rose
Associate Professor
UC San Diego Health System
S. Percy Ivy
Associate Chief
National Cancer Institute
Russell K. Pachynski
Washington University School of Medicine
Nicholas Zorko
Assistant Professor
University of Minnesota
Neeraj Agarwal
Faculty Member
Dana-Farber Cancer Institute
Bradley McGregor
Dana-Farber Cancer Institute
Travis Wheeler
Professor
University of Arizona
Tanya Dorff
Associate Professor
City Of Hope National Medical Center
Dave Hoon
Principal Investigator
The Lundquist Institute
Xiaolei Shi
Assistant professor
University of Maryland Medical Center
David McDermott
Beth Israel Deaconess Medical Center
Veerabhadran Baladandayuthapani
Jeremy M.G. Taylor Collegiate Professor of Biostatistics and Chair of Department of Biostatistics
University of Michigan
Mamta Parikh
Associate Professor
University of California Davis Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.